Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio

Bristol-Myers Squibb (BMY) exceeded Q2 expectations, reporting adjusted EPS of $1.46 and revenue of $12.27 billion, driven by an 18% year-over-year increase in its Growth Portfolio, including strong performances from Opdivo, Breyanzi, and Camzyos. This robust growth, which offset declines in its Legacy Portfolio, prompted BMY to raise its full-year 2025 revenue guidance to $46.5-$47.5 billion. While the company lowered its adjusted EPS forecast to $6.35-$6.65, this primarily reflects a one-time $0.57 per share BioNTech R&D charge, underscoring the company's successful strategic pivot towards newer, high-growth assets.

Analysis

Bristol-Myers Squibb (BMY) reported a strong second quarter, significantly outperforming analyst consensus with adjusted EPS of $1.46 versus an estimated $1.06, and revenue of $12.27 billion against an $11.34 billion forecast. This performance underscores the success of the company's strategic pivot, as its Growth Portfolio generated $6.6 billion in revenue, an 18% year-over-year increase. This robust growth, driven by standout products like Breyanzi (+125% YoY) and Camzyos (+87% YoY), successfully offset a 14% decline in the Legacy Portfolio, which continues to face headwinds from generic competition. The company raised its full-year 2025 revenue guidance, signaling confidence in its commercial execution. While the full-year adjusted earnings forecast was lowered to a range of $6.35-$6.65, this reduction is entirely attributable to a one-time $0.57 per share charge related to an R&D partnership with BioNTech, which should be viewed as a strategic investment in the future pipeline rather than a deterioration in operational profitability.

Key Decisions for Investors

• Investors should look beyond the headline reduction in the EPS forecast, recognizing it is driven by a non-recurring strategic R&D investment, and instead focus on the strong underlying operational performance indicated by the revenue beat and raised sales guidance.
• The primary investment thesis rests on the successful transition to new products; therefore, it is critical to monitor the sales momentum of the Growth Portfolio, particularly for key assets like Breyanzi and Camzyos, in subsequent quarters to validate the sustainability of their high growth rates.
• Given that the company is effectively executing its portfolio transition, as confirmed by the CEO's commentary and strong growth metrics, the modest 2.2% post-earnings stock rise could suggest that the market has not fully priced in the successful de-risking of its patent cliff.